Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fendo.2018.00069 http://scihub22266oqcxt.onion/10.3389/fendo.2018.00069 C5845539!5845539!29559954     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Front+Endocrinol+(Lausanne) 2018 ; 9 (ä): ä Nephropedia Template TP {{tp|p=29559954|t=2018. Proteoglycans?Biomarkers and Targets in Cancer Therapy |pdf=|usr=}}{{29559954}} gab.com Text Proteoglycans Biomarkers and Targets in Cancer Therapy JO: Front Endocrinol (Lausanne) http://www.kidney.de/pget.php?&tw=1&pmid=29559954 #FOAvip Proteoglycans (PGs), important constituents of the extracellular matrix, have been associated with cancer pathogenesis. Their unique structure consisting of a protein core and glycosaminoglycan chains endowed with fine modifications constitutes these molecules as capable cellular effectors important for homeostasis and contributing to disease progression. Indeed, differential expression of PGs and their interacting proteins has been characterized as specific for disease evolvement in various cancer types. Importantly, PGs to a large extent regulate the bioavailability of hormones, growth factors, and cytokines as well as the activation of their respective receptors which regulate phenotypic diversibility, gene expression and rates of recurrence in specific tumor types. Defining and targeting these effectors on an individual patient basis offers ground for the development of newer therapeutic approaches which may act as either supportive or a substitute treatment to the standard therapy protocols. This review discusses the roles of PGs in cancer progression, developing technologies utilized for the defining of the PG ?signature? in disease, and how this may facilitate the generation of tailor-made cancer strategies. Twit Text FOAVip Proteoglycans Biomarkers and Targets in Cancer Therapy ????Front Endocrinol (Lausanne) http://www.kidney.de/pget.php?&tw=1&pmid=29559954 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29559954 #FOAvip English Wikipedia <ref>{{Cite pmid|29559954}}</ref> Proteoglycans?Biomarkers and Targets in Cancer Therapy #MMPMID29559954 Nikitovic D; Berdiaki A; Spyridaki I; Krasanakis T; Tsatsakis A; Tzanakakis GN Front Endocrinol (Lausanne) 2018[]; 9 (ä): ä PMID29559954show ga Proteoglycans (PGs), important constituents of the extracellular matrix, have been associated with cancer pathogenesis. Their unique structure consisting of a protein core and glycosaminoglycan chains endowed with fine modifications constitutes these molecules as capable cellular effectors important for homeostasis and contributing to disease progression. Indeed, differential expression of PGs and their interacting proteins has been characterized as specific for disease evolvement in various cancer types. Importantly, PGs to a large extent regulate the bioavailability of hormones, growth factors, and cytokines as well as the activation of their respective receptors which regulate phenotypic diversibility, gene expression and rates of recurrence in specific tumor types. Defining and targeting these effectors on an individual patient basis offers ground for the development of newer therapeutic approaches which may act as either supportive or a substitute treatment to the standard therapy protocols. This review discusses the roles of PGs in cancer progression, developing technologies utilized for the defining of the PG ?signature? in disease, and how this may facilitate the generation of tailor-made cancer strategies. äProteoglycans?Biomarkers and Targets in Cancer Therapy (epmc).pdf DeepDyve Pubget Overpricing